INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $559,667 | +63.9% | 30,187 | -2.2% | 0.00% | +100.0% |
Q2 2023 | $341,500 | -38.9% | 30,877 | -25.8% | 0.00% | -50.0% |
Q1 2023 | $558,957 | +35.5% | 41,620 | +24.8% | 0.00% | +100.0% |
Q4 2022 | $412,564 | +16.9% | 33,352 | +31.7% | 0.00% | 0.0% |
Q3 2022 | $353,000 | -3.8% | 25,331 | -4.8% | 0.00% | 0.0% |
Q2 2022 | $367,000 | -32.0% | 26,601 | -19.9% | 0.00% | 0.0% |
Q1 2022 | $540,000 | -0.2% | 33,200 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $541,000 | +4.4% | 33,200 | -4.9% | 0.00% | 0.0% |
Q3 2021 | $518,000 | -25.7% | 34,900 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $697,000 | -13.4% | 34,900 | 0.0% | 0.00% | -50.0% |
Q1 2021 | $805,000 | -11.9% | 34,900 | -5.7% | 0.00% | 0.0% |
Q4 2020 | $914,000 | -47.0% | 37,000 | -11.1% | 0.00% | -50.0% |
Q3 2020 | $1,725,000 | -15.9% | 41,600 | -2.8% | 0.00% | -33.3% |
Q2 2020 | $2,051,000 | -16.0% | 42,800 | +10.3% | 0.01% | -25.0% |
Q1 2020 | $2,443,000 | -46.7% | 38,800 | +4.9% | 0.01% | -27.3% |
Q4 2019 | $4,585,000 | +86.8% | 37,000 | 0.0% | 0.01% | +57.1% |
Q3 2019 | $2,455,000 | -3.0% | 37,000 | +16.4% | 0.01% | 0.0% |
Q2 2019 | $2,530,000 | -25.1% | 31,800 | +5.3% | 0.01% | -30.0% |
Q1 2019 | $3,378,000 | +49.6% | 30,200 | +34.8% | 0.01% | +42.9% |
Q4 2018 | $2,258,000 | -21.3% | 22,400 | -1.3% | 0.01% | -12.5% |
Q3 2018 | $2,868,000 | +50.6% | 22,700 | 0.0% | 0.01% | +60.0% |
Q2 2018 | $1,905,000 | +167.2% | 22,700 | +95.9% | 0.01% | +150.0% |
Q1 2018 | $713,000 | +4.4% | 11,589 | -0.9% | 0.00% | 0.0% |
Q4 2017 | $683,000 | +223.7% | 11,689 | +221.0% | 0.00% | +100.0% |
Q3 2017 | $211,000 | -51.2% | 3,642 | +2.1% | 0.00% | 0.0% |
Q2 2017 | $432,000 | +15.5% | 3,567 | +7.9% | 0.00% | 0.0% |
Q1 2017 | $374,000 | -62.3% | 3,307 | -63.7% | 0.00% | -75.0% |
Q4 2016 | $991,000 | -42.7% | 9,118 | -13.2% | 0.00% | -42.9% |
Q3 2016 | $1,728,000 | +13.2% | 10,500 | -1.9% | 0.01% | +16.7% |
Q2 2016 | $1,527,000 | +6.1% | 10,700 | -4.5% | 0.01% | 0.0% |
Q1 2016 | $1,439,000 | -17.4% | 11,200 | -4.0% | 0.01% | -14.3% |
Q4 2015 | $1,743,000 | -11.9% | 11,670 | -2.2% | 0.01% | -12.5% |
Q3 2015 | $1,979,000 | -33.0% | 11,930 | -2.5% | 0.01% | -20.0% |
Q2 2015 | $2,952,000 | +3.3% | 12,230 | +20.7% | 0.01% | 0.0% |
Q1 2015 | $2,857,000 | +88.5% | 10,130 | +4.2% | 0.01% | +100.0% |
Q4 2014 | $1,516,000 | -30.4% | 9,720 | +5.7% | 0.01% | -37.5% |
Q3 2014 | $2,178,000 | – | 9,200 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WHITE SQUARE CAPITAL LLP | 65,500 | $7,117,000 | 11.05% |
Ghost Tree Capital, LLC | 70,000 | $7,606,000 | 1.83% |
Carmignac Gestion | 2,022,792 | $219,776,000 | 1.71% |
Orbimed Advisors | 1,120,000 | $121,688,000 | 1.55% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 29,555 | $3,211,000 | 1.45% |
Parametrica Management Ltd | 10,814 | $1,175,000 | 1.16% |
BB BIOTECH AG | 255,719 | $27,784,000 | 1.03% |
SECTORAL ASSET MANAGEMENT INC | 74,150 | $8,056,000 | 0.89% |
ALTRINSIC GLOBAL ADVISORS LLC | 188,904 | $20,524,000 | 0.76% |
FALCON POINT CAPITAL, LLC | 45,005 | $4,890,000 | 0.66% |